Your browser doesn't support javascript.
loading
Evaluating sex as a predictive marker for response to bevacizumab in metastatic colorectal carcinoma: Pooled analysis of 3,369 patients in the ARCAD database.
Margalit, Ofer; Harmsen, William S; Shacham-Shmueli, Einat; Voss, Molly M; Boursi, Ben; Wagner, Anna D; Cohen, Romain; Olswold, Curtis L; Saltz, Leonard B; Goldstein, Daniel A; Hurwitz, Herbert; Tebbutt, Niall C; Kabbinavar, Fairooz F; Adams, Richard A; Chibaudel, Benoist; Grothey, Axel; Yoshino, Takayuki; Zalcberg, John; de Gramont, Aimery; Shi, Qian; Lenz, Heinz-Josef.
Afiliación
  • Margalit O; Sheba Medical Center, Ramat-Gan, Israel; Tel-Aviv University, Tel-Aviv, Israel. Electronic address: ofer.margalit@sheba.health.gov.il.
  • Harmsen WS; Department of Quantitative Science Research, Mayo Clinic, Rochester, MN, USA.
  • Shacham-Shmueli E; Sheba Medical Center, Ramat-Gan, Israel; Tel-Aviv University, Tel-Aviv, Israel.
  • Voss MM; Department of Quantitative Science Research, Mayo Clinic, Scottsdale, AZ, USA.
  • Boursi B; Sheba Medical Center, Ramat-Gan, Israel; Tel-Aviv University, Tel-Aviv, Israel.
  • Wagner AD; Department of Oncology, Division of Medical Oncology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
  • Cohen R; Department of Quantitative Science Research, Mayo Clinic, Rochester, MN, USA; Sorbonne University, Department of Medical Oncology, Saint-Antoine Hospital, AP-HP, F-75012 Paris, France; Sorbonne University, INSERM, Unité Mixte de Recherche Scientifique 938, Centre de Recherche Saint-Antoine, Equipe I
  • Olswold CL; Department of Quantitative Science Research, Mayo Clinic, Rochester, MN, USA.
  • Saltz LB; Memorial Sloan Kettering Cancer Centre, New York, NY, USA.
  • Goldstein DA; Rabin Medical Centre, Petach Tikvah, Israel.
  • Hurwitz H; Duke Cancer Institute, Duke University, Durham, NC, USA.
  • Tebbutt NC; University of Melbourne, Australia; Austin Health, Heidelberg, Victoria, Australia.
  • Kabbinavar FF; David Geffen School of Medicine at University of California at Los Angeles, Los Angeles, CA, USA.
  • Adams RA; Cardiff University and Velindre Cancer Centre, Cardiff, UK.
  • Chibaudel B; Department of Medical Oncology, Franco-British Institute, Levallois-Perret, France.
  • Grothey A; West Cancer Center, Germantown, TN, USA.
  • Yoshino T; Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Japan.
  • Zalcberg J; Department of Medical Oncology, Alfred Health and School of Public Health, Monash University, Melbourne, Australia.
  • de Gramont A; Department of Medical Oncology, Franco-British Institute, Levallois-Perret, France.
  • Shi Q; Department of Quantitative Science Research, Mayo Clinic, Rochester, MN, USA.
  • Lenz HJ; Department of Gastrointestinal Oncology, Keck School of Medicine at USC, Los Angeles, CA, USA.
Eur J Cancer ; 178: 162-170, 2023 01.
Article en En | MEDLINE | ID: mdl-36446161
BACKGROUND: Previous studies suggest a possible sex-specific response to bevacizumab in metastatic colorectal carcinoma (mCRC), showing a benefit in males, while the effect in females is less significant. METHODS: Data from 3369 patients with mCRC enrolled on four first-line randomised trials testing chemotherapy with or without bevacizumab (2000-2007) were pooled. Association between sex and progression-free survival and overall survival (OS) was evaluated by stratified Cox regression model, adjusted for potential confounders. Predictive value was evaluated by interaction effect between sex and treatment. In a pre-planned secondary analysis, analyses were stratified using an age cut point of 60 years to evaluate the possible role of menopausal-related effects. RESULTS: Bevacizumab was associated with an improved median OS in males and females, with a 2.3- and 0.6-months benefit, respectively. Stratified by age, bevacizumab resulted in improved OS in males at both age categories. In females at or above the age of 60 (n = 731), bevacizumab resulted in improved OS. However, in females below the age of 60 (n = 634), OS benefit did not reach statistical significance (adjusted hazard ratio = 0.94, 95% confidence interval 0.74-1.20). CONCLUSIONS: Our results confirmed the OS benefit from the addition of bevacizumab to first-line chemotherapy in mCRC in both sexes. Among females, the benefit was less than 1 month. For females under the age of 60, there was no survival benefit. These findings could be used to relieve financial toxicity or be redistributed within healthcare systems for other health-related purposes.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Colorrectales / Bevacizumab Tipo de estudio: Clinical_trials / Prognostic_studies / Risk_factors_studies Límite: Female / Humans / Male / Middle aged Idioma: En Revista: Eur J Cancer Año: 2023 Tipo del documento: Article Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Colorrectales / Bevacizumab Tipo de estudio: Clinical_trials / Prognostic_studies / Risk_factors_studies Límite: Female / Humans / Male / Middle aged Idioma: En Revista: Eur J Cancer Año: 2023 Tipo del documento: Article Pais de publicación: Reino Unido